DealsJun 4, 2026, 08:06 AM
MIRA Pharma Secures Worldwide Exclusive Rights for MIRA-55 & SKNY-1
AI Summary
MIRA Pharmaceuticals, Inc. entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs. This agreement grants MIRA global rights to develop, manufacture, commercialize, and sublicense products covered by the licensed intellectual property, along with intellectual property enforcement rights. The amendment consolidates the company's IP portfolio and establishes a unified global rights structure across its core therapeutic assets, without materially changing the existing economic terms.
Key Highlights
- MIRA Pharmaceuticals secured worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs.
- The agreement grants MIRA global rights for development, manufacturing, commercialization, and sublicensing.
- MIRA also gains worldwide intellectual property enforcement rights for the licensed assets.
- The amendment consolidates MIRA's intellectual property portfolio and unifies global rights across its pipeline.
- MIRA-55 is an investigational drug candidate for chronic inflammatory pain.
- SKNY-1 is an investigational drug candidate for obesity and addiction-related disorders.
- The core economic terms of the existing license arrangements were not materially modified.
Price Impact
More from MIRA